Hideko Nakahara

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Norihiro Nishimoto, Kimio Terao, Toru Mima et al. · Blood · 2008 · 810 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

Norihiro Nishimoto, Yuzuru Kanakura, Katsuyuki Aozasa et al. · Blood · 2005 · 750 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +12

Anti–interleukin‐6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis

Hideko Nakahara, Jian Song, Masamichi Sugimoto et al. · Arthritis & Rheumatism · 2003 · 396 citations

Medicine, Clinical Sciences, Immunology +14

Successful treatment of a patient with takayasu arteritis using a humanized anti–interleukin‐6 receptor antibody

Norihiro Nishimoto, Hideko Nakahara, Naoko Yoshio‐Hoshino et al. · Arthritis & Rheumatism · 2008 · 180 citations

Life Sciences, Immunology, Pharmacotherapy +17

A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years

Hideko Nakahara, Toru Mima, Naoko Yoshio‐Hoshino et al. · Modern Rheumatology · 2008 · 56 citations

Life Sciences, Immunology, Pharmacotherapy +15